Featured Post:
The unequal burden: Prostate cancer hits Black men harder. Can the gap be closed?
By: Chidiebube Chikezie
Although it affects all men, Black men are twice as likely to develop prostate cancer. Can the gap be closed?
Read PostFeatured Post:
By: Chidiebube Chikezie
Although it affects all men, Black men are twice as likely to develop prostate cancer. Can the gap be closed?
Read PostSubscribe to receive our latest blog posts covering a wide range of topics, from groundbreaking discoveries to cutting-edge advancements and industry trends.
BioQuick News | Jan 25, 2024
GenomeWeb | Sep 1, 2023
Cancerworld | Feb 23, 2023
Oxford BioDynamics PLC (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT predicts how a patient will respond to immune checkpoint inhibitor therapies. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.
OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.
Learn About OBD